Abstract Beatriz Honorato¹, Juan Alcalde², Rafael Martinez-Monge³, Natalia Zabalegui⁴ and Jesús Garcia-Foncillas¹

¹Clinical Genetics Unit and Oncology Department, University Clinic of Navarra, Pamplona, Spain. ²Otolaringology Department, University Clinic of Navarra, Pamplona, Spain. ³Radiotherapy-Oncology Department, University Clinic of Navarra, Pamplona, Spain. ⁴Immunotherapy Laboratory, CIMA University of Navarra, Pamplona, Spain.

Abstract

Resistance to radio and chemotherapy is one of the major drawbacks in the progression of head and neck squamous cell cancer (HNSCC) patients, evidencing the importance of finding optimum molecular prognosis markers to develop personalized treatment schedules. TGF-β effector TAK1 activity has been related to a greater aggressiveness in several types of cancer (Kondo et al. 1998; Edlund et al. 2003; Kaur et al. 2005) and, although there has been described no significant implication of TAK1 in HNSCC development, we have further examined the role of its mRNA expression as a marker of prognosis in HNSCC. Fifty-nine advanced HNSCC patients were recruited for the study. The tumor expression of TAK1 mRNA was analyzed with RT-PCR using Taqman technology and its relationship with the clinical outcome of the patients studied. TAK1 mRNA expression was lower in patients that relapsed than in those that did not, but the difference was only significant between the patients that showed response to treatment (p < 0.001). ROC curve analyses pointed a 0.5 expression ratio TAK1/B2M value as an optimum cut-off point for relapse and response. Our data suggest the TAK1 mRNA analysis by Taqman RT-PCR can predict the risk of relapse in HNSCC patients.

Discussion
No comments yet...Be the first to comment.

 CONNOTEA  CITEULIKE FACEBOOK LINKED IN